Questions about the clinical meaningfulness of the primary endpoint and the potential for long-term neurodevelopmental issues will frame some of the discussion Thursday as the FDA's Pediatric Advisory Committee and Gastrointestinal Drugs Advisory Committee consider the risk-benefit profile of Infacare Pharmaceutical Corp.'s stannsoporfin injection.